•  

     

     

    World Orphan Drug Congress

    BARCELONA, NOVEMBER 14-15, 2017
    PRE-CONGRESS WORKSHOPS 13 NOVEMBER

    STRATEGY, ADVOCACY AND PARTNERING FOR THE ORPHAN DRUG INDUSTRY

    World Orphan Drug Congress

     

2017 PROSPECTUS

Get your brand, your message and your sales people in front of your customers.

The Congress opens doors to fantastic opportunities to form lucrative partnerships and source new ground-breaking solutions.

 

DOWNLOAD NOW

World Orphan Drug Congress 2017  sponsorship prospectus

OUR HISTORY

 

The 8th annual World Orphan Drug Congress is the marketplace for orphan drug professionals looking at the complete value chain of orphan drug development, from clinical development and R&D to corporate development and market access.

Being Europe’s largest Orphan Drug Congress, this event will provide a platform for you to showcase your thought leadership and expertise pharma, biotechs, payers, regulators and patient advocates.

 

 

2017 ADVISORY BOARD

 

2017 ADVISORY BOARD

EUROPE’S MEETING PLACE FOR THE RARE DISEASE COMMUNITY

The Conference offers strategic keynote plenaries, themed tracks and dedicated networking sessions, you have the chance to really tailor the event to the needs of your day-to-day role. 

The Exhibitors  have a unique opportunity to put their business products and services in front of potential buyers looking to source the latest technologies in the orphan drugs industry. 

The pre-congress workshops will offer insights into Pricing, Reimbursement and Market Access Challenges and Accelerating Commercialization of Rare Disease Treatments in the afternoon.

Meet and listen to biotech start-ups and investors in our Pitch & Partner track where the most promising companies showcase their orphan drug technology and pipeline.

Enjoy discussions on: 

FUTURE OF ORPHAN DRUGS

PRICING & REIMBURSEMENT

APPROVAL & ACCESS

M&A AND COMMERCIALIZATION

PATIENT-CENTRIC RESEARCH

REAL-WORLD EVIDENCE

MARKETING & COMPETITIVENESS

GENE THERAPY

SCIENTIFIC INNOVATION

REGIONAL MARKET ANALYSIS

BIOSIMILARS

ROUNDTABLES

Colocated with:

Rare Disease Advocacy World Logo

Pitch and Partner Logo

 

PAST SPEAKERS

 

  • Yann Le Cam at World Orphan Drug Congress
    Yann Le Cam
    Chief Executive Officer
    EURORDIS
    Ms Segolene Ayme at World Orphan Drug Congress
    Ms Segolene Ayme
    Founder of Orphanet & Emeritus Research Director
    Inserm
    Kristina Larsson at World Orphan Drug Congress
    Kristina Larsson
    Head of Orphan Drugs
    E.M.A.
  • Klaus-Dieter Langner at World Orphan Drug Congress
    Klaus-Dieter Langner
    CSO
    Grunenthal
    Sheela Upadhyaya at World Orphan Drug Congress
    Sheela Upadhyaya
    Assoc. Director Highly Specialised Technologies
    National Institute For Health and Care Excellence
    Paul Strijbos at World Orphan Drug Congress
    Paul Strijbos
    Global Head Rare Diseases Clinical Development
    F. Hoffmann-La Roche
  • Ms Ruxandra Draghia Akli at World Orphan Drug Congress
    Ms Ruxandra Draghia Akli
    Deputy Director General
    European Commission
    Vinciane Pirard at World Orphan Drug Congress
    Vinciane Pirard
    Senior Director Public Affairs Europe
    Genzyme Europe B.V
    Kristin Svanquist at World Orphan Drug Congress
    Kristin Svanquist
    Head of unit for HTA and reimbursement
    Norwegian Medicines Agency
  • Ms Gemma Gatta at World Orphan Drug Congress
    Ms Gemma Gatta
    Head of Unit at S.S. Evaluative Epidemiology
    Italian Institute of Tumors
    Robert Bezar at World Orphan Drug Congress
    Robert Bezar
    Director Medical, SMA Lead Europe and Canada
    Biogen International GmbH
    Andrzej Rys at World Orphan Drug Congress
    Andrzej Rys
    Director of Health Systems and Products
    SANCO - Directorate General for Health and Consumers
  • Professor Lieven Annemans at World Orphan Drug Congress
    Professor Lieven Annemans
    Professor of Health Economics
    Gent University
    Gero Struebbe at World Orphan Drug Congress
    Gero Struebbe
    Global Market Access Director
    Novartis
    Joseph Musumeci at World Orphan Drug Congress
    Joseph Musumeci
    Senior Advisor
    BluePrint Orphan

 

SEE MORE

"It is an important meeting that sheds light on the value patient advocates bring to the development process!"

Global Medicines Development Lead - Rare Diseases, Pfizer

 

OUR SPONSORS & EXHIBITORS

 

  • Platinum Sponsor

    Mapi Group at World Orphan Drug Congress

    Gold Sponsor

    INC Research at World Orphan Drug Congress
  • Gold Sponsor

    P.R.A. Health Sciences at World Orphan Drug Congress

    Gold Sponsor

    Premier Research at World Orphan Drug Congress
  • Gold Sponsor

    QuintilesIMS at World Orphan Drug Congress

    Silver Sponsor

    Medical Marketing Economics at World Orphan Drug Congress
  • Bronze Sponsor

    Cello Health at World Orphan Drug Congress

    Bronze Sponsor

    Komtur Polska sp. z.o.o at World Orphan Drug Congress
  • Bronze Sponsor

    Raremark at World Orphan Drug Congress

    Bronze Sponsor

    SKC Beratungsgesellschaft at World Orphan Drug Congress
  • Bronze Sponsor

    Worldwide Clinical Trials at World Orphan Drug Congress

 

"The information provided was really helpful, I will use it in my daily work. The networking was also great!" 

 

Director, Value Evidence Lead Rare Diseases, GSK

PAST ATTENDEES

 

AANORA Actelion Pharma Ltd Action Duchenne Addmedica Adelphi Values AGSD (UK) AirLiquide

AKU Society Alcimed Alexion Pharmaceuticals Allaysis LLC Alliance Life Sciences ALS Liga Belgi

Alstrom Syndrome U.K. AMICULUM Anticancer Fund AOP Orphan Pharmaceuticals AG

ArmaGen Technologies, Inc. Atacsia a Fi / Ataxia and Me Ataxia UK aTyr aTyr Pharma

BioBlast Pharma Ltd Biopontis Alliance Blackswan Foundation Brace Pharma Capital

Caligor Rx, Inc. Calypso Biotech SA  Capsugel Celgene Centogene AG

Charity Association Neurohereditary Diseases Chiesi Farmaceutici Spa Clear Pharma

Clinart MENA Clinerion Clinigen Global Access Programs Comradis Concenter BioPharma/Silkim Ltd.

Cote Orphan Coulter Partners   Covance UK CRF Health CureDuchenne Cures Within Reach

Cydan Development  Cytokinetics Daiichi Sankyo Europe GmbH Dipharma SA Diurnal Limited

Dravet Syndrome Foundation Durbin E.C.R.I.N. ECRIN-ERIC ELA Suisse

Emmaus Life Sciences, Inc Ergomed EspeRare Euromedica EuropaBio

European Huntington's Disease Network EURORDIS  Euticals Spa EvaluatePharma Ltd

Evidera F.Hoffmann-La Roche Ltd. Facio Therapies BV Federal Joint Committee

F Hoffmann-La Roche French Association Against Friedreich Ataxia Gaucher Disease Russia

Genesis Pharma Genetic Alliance U.K. Genkyotex Innovation Sas Genpharm Genzyme Europe BV

Gerson Lehrman Group Giddi Pharma GlaxoSmithKline  Greenovation Biotech GmbH

Grünenthal GmbH GSK Rare Diseases GW Pharmaceuticals   Haute Autorite De Sante

Horizon Pharma Inc I.M.S. Health Idis Managed Access Idis Pharma

Imagine - Institut des Maladies génétiques IMS Health INC Research Index Ventures INSERM

 Lysogene M3 Pharma S/A Mapi Consultancy Midas Pharma GmbH Minoryx Therapeutics

MPS Society N.O.R.D. National Institute for Health and Care Excellence

National Institutes of Biomedical Innovation, Health and Nutrition

National organisation for rare diseases of Serbia  NephCure Kidney International Niemann-Pick UK Novartis

 

DOWNLOAD THE POST EVNT REPORT